drugset / Trial / NCT02338713

Effect of Calcium 500 mg and Vitamin D3 1000 IU Chewable Tablet on Intestinal Calcium Absorption

NCT02338713

Phase 1 Completed 27 enrolled Takeda
NaSingle-groupOpen-labelBasic science

Summary

The purpose of this study is to demonstrate that the intestinal absorption of calcium from a novel calcium carbonate-vitamin D3 chewable tablet formulation (calcium 500 milligrams (mg) and vitamin D3 1000 International Units (IU)) increases the amount of calcium excreted in urine and decreases parathyroid hormone (PTH) in serum as compared with Baseline.

Timeline

Start
2015-01
Primary completion
2015-02
Completion
2015-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Calcium carbonate Other / unclassified 500 mg
Subject Cholecalciferol Other / unclassified 1000 iu

Indications

No indication recorded.